Clinical trials
Primary IgA Nephropathy clinical trials
Below are recruiting primary iga nephropathy clinical trials, each written for real people, not researchers. We’re tracking 35 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07498335RecruitingPhase 3
Atrasentan for children with IgA nephropathy
This trial tests an experimental medicine called atrasentan for children aged 2 to under 18 with IgA nephropathy, a kidney disease. The study aims to see if the drug can help protect kidney function and reduce protein in the urine, with fewer side effects than current treatments.
Neptune City, New JerseyAges 2–18 - NCT07750249Enrolling by invitationEarly Phase 1
Short-chain fatty acids for IgA nephropathy
This trial tests whether a daily supplement of short-chain fatty acids (SCFAs) can slow down kidney damage in people with IgA nephropathy. SCFAs are substances made by gut bacteria that may help reduce inflammation and protect the kidneys.
MartinAges 18 years+ - NCT07582133RecruitingPhase 2
Long-term safety study of HRS-5965 for IgA kidney disease
This study follows up on patients who participated in a previous trial (HRS-5965-305) testing a drug called HRS-5965 for IgA nephropathy, a kidney disease where the immune system damages the kidneys. Researchers want to check if the drug continues to be safe and well-tolerated over a longer period.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06466135RecruitingPhase 2
Study of WAL0921 for glomerular kidney diseases
This study tests a new drug called WAL0921 for people with certain types of kidney disease. The goal is to see if it can help protect kidney function.
Los Angeles, CaliforniaAges 18–75 - NCT06676007Recruiting
Early use of a targeted budesonide for IgA nephropathy
This trial tests starting a special form of budesonide (Nefecon) early in people with IgA nephropathy, a kidney disease. The goal is to see if it can reduce protein in the urine and protect kidney function.
Chengdu, SichuanAges 18–75 - NCT06676384RecruitingPhase 4
Testing additional drugs for IgA nephropathy in South Asian patients
This trial is testing if adding another approved drug to standard treatment can slow kidney function decline in people with IgA nephropathy. It aims to find better options for South Asian adults with this condition.
Nadiād, GujaratAges 18–65 - NCT06712407RecruitingPhase 4
Extended TARPEYO treatment for IgA nephropathy
This study tests whether taking TARPEYO (budesonide) for longer than 9 months is safe and effective for adults with IgA nephropathy. It's for people who have already completed a 9-month course of TARPEYO and are on stable blood pressure medication.
Birmingham, AlabamaAges 18 years+ - NCT07014826RecruitingPhase 3
Trial of HRS-5965 for IgA kidney disease
This phase 3 trial tests an experimental drug (HRS-5965) for people with IgA nephropathy (a kidney disease). It aims to find out if the drug can help reduce protein in the urine and protect kidney function. To join, you must have had a kidney biopsy showing IgA nephropathy within the past 8 years and have significant protein in your urine despite taking standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07074951Recruiting
Tonsillectomy and immune therapy for high-risk IgA kidney disease
This trial tests whether removing the tonsils (tonsillectomy) plus immune-suppressing therapy can help people with a high-risk form of IgA nephropathy, a kidney disease. It aims to slow down kidney damage and delay the need for dialysis.
Saint PetersburgAges 18–75 - NCT07305974RecruitingPhase 2
Study of RG002C0106 for primary IgA nephropathy
This phase 2a trial tests an experimental drug called RG002C0106 in people with primary IgA nephropathy. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
Beijing, Beijing MunicipalityAges 18–65 - NCT07354932RecruitingPhase 2
Testing SHR-2173 for IgA Nephropathy
This trial tests a new drug, SHR-2173, for people with IgA nephropathy who still have a lot of protein in their urine despite standard care. The goal is to see if it can help protect kidney function.
Guangzhou, GuangdongAges 18 years+ - NCT07498673RecruitingEarly Phase 1
Testing YKST02 for IgA nephropathy
This early-phase study tests a new drug called YKST02 for people with primary IgA nephropathy, a kidney disease. It aims to see if the drug is safe and if it can help reduce kidney damage.
Wuhan, HubeiAges 18–75 - NCT07585981Recruiting
Budesonide capsules for IgA kidney disease
This trial tests whether a special steroid capsule called budesonide can help treat IgA nephropathy, a kidney disease where your immune system damages the kidneys. You would take this medication along with standard care to see if it slows kidney damage and reduces protein in your urine.
BeijingAges 18 years+ - NCT07616700RecruitingPhase 2
Long-term safety study of HSK39297 for IgA kidney disease
This study continues treatment with an experimental medicine called HSK39297 for people with IgA nephropathy, a condition where the immune system damages the kidneys. The trial will track how safe and effective the medicine is over time in people who already completed an earlier study.
BeijingAges Any age - NCT04858724Recruiting
IgA nephropathy patient registry for long-term outcomes
This study gathers information from people with IgA nephropathy to better understand how the disease changes over time and what can be expected. The goal is to improve care and help guide future treatments.
Shanghai, Shanghai MunicipalityAges Any age - NCT06819826RecruitingPhase 3
Study of SC0062 for IgA Nephropathy with Proteinuria
This trial tests an experimental drug (SC0062 capsule) for people with IgA nephropathy who have protein in their urine. It aims to see if the drug can help reduce kidney damage when added to standard treatments like blood pressure medications.
Guangzhou, Yuexiu DistrictAges 18 years+ - NCT07056595Recruiting
Finerenone for IgA nephropathy patients
This trial tests whether finerenone can help people with IgA nephropathy, a kidney disease. It is for adults with high protein in their urine who are already on standard kidney-protecting medications.
MoscowAges 18 years+ - NCT02954419Recruiting
Biomarker study in kidney disease caused by IgA
This study looks at lab markers (“biomarkers”) in people with IgA nephropathy, using kidney biopsy tissue. It may help researchers find better ways to understand the disease and tailor future care.
Guangzhou, GuangdongAges 14 years+ - NCT07182227RecruitingPhase 1/Phase 2
Gene therapy PS-002 for IgA nephropathy
This trial tests a new gene therapy called PS-002 for adults with IgA nephropathy. It aims to see if the treatment is safe and can help reduce protein loss in urine and protect kidney function.
Miami, FloridaAges 18 years+ - NCT07390123RecruitingPhase 3
Study of HSK39297 for IgA Nephropathy (IgAN)
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
Huangshan City, AnhuiAges 18 years+ - NCT03001947Recruiting
Study for people with biopsy-proven IgA kidney disease
This trial enrolls teens and adults with biopsy-proven IgA nephropathy to help doctors learn whether a specific care approach works better for high-quality treatment. It is meant for people whose IgA kidney disease is the primary form (not caused by another illness).
Guangzhou, GuangdongAges 14 years+ - NCT07606352RecruitingPhase 2
STL303 Safety and Efficacy for IgA Kidney Disease
This trial tests a new drug called STL303 for patients with IgA nephropathy, a type of kidney disease where IgA (an antibody) builds up and damages kidneys. The study aims to see if STL303 is safe and can help slow kidney damage in people whose current blood pressure medications alone aren't controlling their protein loss.
Woolloongabba, QueenslandAges 18 years+ - NCT06065852Recruiting
National registry for rare kidney diseases
This study creates a registry to collect health information from people with rare kidney diseases. It aims to improve understanding and future treatments by tracking patient experiences.
Bristol, South WestAges Any age - NCT07541287RecruitingPhase 2
JADE101 for IgA Nephropathy Kidney Disease
This study tests whether JADE101, a new medicine, can help slow kidney damage in people with IgA nephropathy (a type of kidney disease caused by immune system problems). You'll take it alongside your current blood pressure medications for about 48 weeks.
Chula Vista, CaliforniaAges 18–60
Hear when a new Primary IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for primary iga nephropathy?
- Yes. Clin2 currently lists 35 recruiting primary iga nephropathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a primary iga nephropathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a primary iga nephropathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.